Cardiovascular Disease After Aromatase Inhibitor Use
Open Access
- 1 December 2016
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 2 (12), 1590-1597
- https://doi.org/10.1001/jamaoncol.2016.0429
Abstract
Aromatase inhibitors (AIs) are considered superior to tamoxifen citrate in reducing recurrence risk in postmenopausal women with hormone receptor–positive breast cancer.1,2 However, although tamoxifen has favorable effects on lipid profiles, AIs have unfavorable effects, raising questions on whether these 2 therapies differentially affect cardiovascular disease (CVD) risk.3-9Keywords
This publication has 2 references indexed in Scilit:
- Faculty Opinions recommendation of Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.Published by H1 Connect ,2015
- Faculty Opinions recommendation of Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.Published by H1 Connect ,2013